Dr. Christian Capitini joined the faculty of the University of Wisconsin-Madison in 2011, and is presently an American Cancer Society Research Scholar and a Young Investigator on a Pediatric Cancer Dream Team sponsored by the St. Baldrick’s Foundation and Stand up to Cancer. Dr. Capitini leads an NIH and NSF-supported laboratory focusing on development of cell-based therapies including NK cells and CAR T cells for the treatment of childhood cancers like neuroblastoma and osteosarcoma. His laboratory was the first to track NK cells within tumors using fluorine-19 MRI. The laboratory also manufactures cell-based therapies for complications of bone marrow transplant, including alternatively activated macrophages to treat graft-versus-host-disease and acute radiation syndrome. In the clinic, Dr. Capitini was a site Principal Investigator (PI) for the first multicenter CAR T cell trial, leading to FDA approval of tisagenlecleucel (Kymriah). Presently he is a site PI for multiple Kymriah trials for the upfront treatment of B cell leukemia and for recurrent non-Hodgkin lymphoma.